Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide-Reference-Cited by-同舟云学术

Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide

Published:2023-01-01 Issue:1 Volume:92 Page:67-75
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Palella Frank J.,Hou Qingjiang,Li Jun,Mahnken Jonathan,Carlson Kimberly J.,Durham Marcus,Ward Douglas,Fuhrer Jack,Tedaldi Ellen,Novak Richard,Buchacz Kate

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference16 articles.

1. Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor–based regimens;Norwood;JAIDS J Acquired Immune Deficiency Syndromes,2017

2. Serum leptin level mediates the association of body composition and serum C-reactive protein in HIV-infected persons on antiretroviral therapy;Koethe;AIDS Res Hum Retroviruses,2012

3. The HIV outpatient study 25 Years of HIV patient care and epidemiologic research;Buchacz;Open Forum Infect Dis.,2020

4. Risk factors for weight gain following switch to integrase inhibitor–based antiretroviral therapy;Lake;Clin Infect Dis.,2020

5. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials;Sax;Clin Infect Dis.,2020

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Weight Gain and Antiretroviral Therapy;Infectious Disease Clinics of North America;2024-09

2. Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone Metabolism;Current HIV/AIDS Reports;2024-08-29

3. Switch to fixed-dose ainuovirine, lamivudine, and tenofovir DF versus elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed people living with HIV-1: the 48-week results of the SPRINT trial, a multi-centre, randomised, double-blind, active-controlled, phase 3, non-inferiority trial;The Lancet Regional Health - Western Pacific;2024-08

4. Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration;The Lancet HIV;2024-08

5. Contemporary Treatment Approaches for Human Immunodeficiency Virus Infection;Nursing Clinics of North America;2024-06